This year’s eyeforpharma Barcelona conference might have seemed all doom and gloom at the outset, with many predicting the downfall of pharma as we know it – but there were plenty of speake
The European Commission has approved Sanofi and Regeneron’s Praluent for reducing cardiovascular risk in adults with established atherosclerotic CV disease (ASCVD), giving the drug another advan
Sanofi has moved a step closer to getting its new diabetes therapy Zynquista approved in Europe, with a positive opinion from the Committee for Medicinal Products for Human Use (CHMP).
Sanofi and Regeneron’s attempts to make Dupixent into a blockbuster franchise have been boosted with more strong phase 3 results in patients with chronic rhinosinusitis with nasal polyps (CRSwNP
Sanofi has become the latest big pharma firm to appoint a chief digital officer, choosing Ameet Nathwani to take up the position, adding onto his current role of executive vice president, c
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.